Felzartamab in Antibody-Mediated Rejection

N Engl J Med. 2024 Sep 26;391(12):1162. doi: 10.1056/NEJMc2409970.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized* / administration & dosage
  • Antibodies, Monoclonal, Humanized* / adverse effects
  • Clinical Trials, Phase II as Topic
  • Graft Rejection* / drug therapy
  • Graft Rejection* / immunology
  • Graft Rejection* / pathology
  • Graft Survival / drug effects
  • Graft Survival / immunology
  • Humans
  • Kidney Transplantation / adverse effects
  • Kidney Tubules / drug effects
  • Kidney Tubules / immunology
  • Kidney Tubules / pathology
  • Randomized Controlled Trials as Topic

Substances

  • Antibodies, Monoclonal, Humanized
  • felzartamab